A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Bipolar disorder
BD is a psychiatric disorder characterized by extreme mood swings, ranging between episodes of acute euphoria mania and severe depression. There are many anecdotal reports which suggest that some bipolar sufferers use cannabis to reduce or even alleviate the symptoms of both mania and depression.
The prescribed medications for treating BD are mood stabilizers, which are used to prevent or control episodes of mania and/or depression. Many individuals require a combination of medications to achieve relief from the symptoms, Doctors use trial and error to find the optimum combination and it can take many months to stabilise a patient.
The risk of suicide is a consideration in BD, with some estimates as high as 10–15%.
CBD – The Quest for Therapeutic Targets
“Experimental studies suggest that high-dose CBD may decrease anxiety and increase mental sedation in healthy individuals. Clinical trials suggest the high-dose CBD may be useful for the treatment of social anxiety disorder, and possibly, insomnia and epilepsy”
Download the .pdf: Here
Multiple mechanisms involved in therapeutic potential of CBD in psychiatric disorders
“The therapeutic use of CBD in psychotic patients was tested for the first time in 1995. In an open, case report study, a 19-year-old black schizophrenic female patient, who presented serious side effects after treatment with conventional antipsychotics, received increasing oral doses of CBD (up to 1500mg) for four weeks. A significant improvement with no side effects was observed in all items of the standard brief psychiatric rating scale (BPRS) during CBD treatment, with an efficacy similar to that of haloperidol”
Download the .pdf: Here
Antidepressant effect of THC and other cannabinoids
“In conclusion, our results show that phytocannabinoids, including Δ 9 -THC, CBD, and CBC, exert antidepressant-like actions in animal models of behavioural despair. The exact mechanism underlying such activity is still unclear and confounded by the fact that these compounds have varying binding profiles to the established cannabinoid CB1 as well as to non CB1 receptors. The results support the effect of phytocannabinoids on mood disorders and provide potential leads for further studies.
Download the .pdf: Here